GLP-1 medication therapy is not a quick fix but a gradual process that helps patients achieve their weight loss goals steadily and safely
Peptides require metabolic support, adequate protein intake, and consistent use to take effect
In a normal patient, PIH risk is manageable and largely predictable based on Fitzpatrick skin type and careful parameter selection
The inhibitory effect of GLP-1R agonists on food intake has been demonstrated in a number of species, including non-human primates [54] and humans [55]
It is also important to recognize that the biological effects of GO are dose- and time-dependent, while certain concentrations can scavenge ROS, higher levels may trigger oxidative stress, negatively affecting cell health
Your body is adapting to significantly lower calorie intake, potential GI side effects, and altered energy availability